Syngulon
Rue Du Bois Saint Jean 15/1
4102 Seraing
BE
Syngulon
Foundation date
07/03/2013
Sector
#Biotechnology - otherSubsector
Syngulon is developing original genetic technologies to improve the efficiency of microorganisms.Syngulon has introduced a new genetic technology (US Patent 9,333,227, issued on May 10, 2016) for the use of bacteriocin/immunity in any bacteria, yeast or algae for controlled growth of microorganisms.This issued patent is part of a new worldwide patent portfolio developed by Syngulon and available for licensing in all fields of use on a non-exclusive basis.
Upcoming events
All events-
0712 '22
Emerging Applications of Microbes (2nd edition)
Event by: VIB -
1212 '22
Type 2 Immunity in Homeostasis and Disease (2nd edition)
Event by: VIB -
2911 '22
BioFIT 2022
Event by: Eurasanté
Latest news
More news-
Indigo Diabetes announces first participant enrolled in the SHINE clinical trial
17 hours ago
Read more
-
FINTEPLA®▼ (fenfluramine) approved in Japan for the treatment of seizures associated with Dravet syndrome
Tuesday September 27th 2022
Read more
-
Pauwels Consulting takes over Science@Work
Friday September 23rd 2022
Read more